Timothy M. O'Brien 

Timothy O'Brien concentrates his practice in the areas of product liability, personal injury, wrongful death, and mass tort litigation. He has been appointed co-lead counsel in In re Cisco Systems Securities Litig., MDL No. 1527, as discovery co-chair in In re Accutane Products Liab. Litig., MDL No. 1626, as discovery co-chair in In re Medtronic, Inc., Implantable Defibrillators Product Liab. Litig., MDL No. 1726, as a member of the Plaintiffs Steering Committee in In re Guidant Corp. Implantable Defibrillators Product Liab. Litig., MDL No. 1708, and served on the discovery committee of In re Phenylpropanolamine ("PPA") Product Liab. Litig. , MDL No. 1407.

As a trial lawyer, Mr. O'Brien has received numerous multi-million dollar verdicts and judgments, the most recent of which include a 2006 judgment in the amount of $12 million for a brain-damaged child, a 2006 wrongful death verdict in the amount of $2.4 million for the death of a construction superintendent, a 2007 automobile wreck verdict in the amount of $1.2 million for the non-paralyzing fracture of a cervical vertebra, and a 2007 $7 million verdict against pharmaceutical company Hoffman-LaRoche, Inc., on behalf of a young man who developed inflammatory bowel disease as a result of taking the popular acne medication, Accutane. As the partner responsible for Levin Papantonio's PPA litigation, he has secured over $30 million in settlements for the firm's clients.

Additionally, Mr. O'Brien has served as national co-lead counsel in the Cisco securities litigation which recently concluded with a $100 million settlement for the Cisco shareholders. He has taken the national lead in prosecuting Fosamax osteonecrosis of the jaw cases and has been interviewed and extensively quoted in The Wall Street Journal, New York Times, The Pink Sheet , The Associated Press, Bloomberg News, and by National Public Radio, CBS Radio, and Air America Radio.

In late 2006, the United States District Court for the Southern District of New York appointed Mr. O'Brien Lead Counsel for MDL No. 1789, In re Fosamax Products Liability Litigation .

In recognition of his accomplishments representing the injured, Mr. O'Brien was recently chosen as one of the 2007 Super Lawyers by the annual publication of the same name.

Mr. O'Brien earned his Bachelor of Arts degree from the University of Virginia in 1992 (with distinction) and earned his Juris Doctorate degree at the University of Florida College of Law in 1995 (with honors). During law school, Mr. O'Brien served as Vice Chairman of the Moot Court Board and also received the University of Florida College of Law Award for Appellate Advocacy.

After graduating from law school, Mr. O'Brien worked for two years as a law clerk for the Honorable William T. Moore, Jr., United States District Judge for the Southern District of Georgia. Mr. O'Brien then entered private practice in Georgia where he concentrated his practice in the area of federal litigation. During his period of private practice in Georgia, Mr. O'Brien, together with Judge Moore, coauthored Of Clients and Fees: Ethical Issues for Criminal Defense Attorneys, Vol 4:4 Georgia Bar Journal 10 (1999). In the Summer of 2000, Mr. O'Brien returned to his hometown of Pensacola and began working with Levin, Papantonio.

Mr. O'Brien, a member of the Florida Bar, the Georgia Bar, and the Mississippi Bar, is presently licensed to practice in the following courts: all State Courts in Florida; all State Courts in Georgia; all State Court in Mississippi; the United States Supreme Court; the United States Court of Appeals for the Eleventh Circuit; the United States Court of Appeals for the Ninth Circuit; the United States Court of Appeals for the Fifth Circuit; the United States Court of Appeals for the Federal Circuit; and the United States District Courts for Northern District and Middle District of Florida, the Southern District, Middle District, Northern District of Georgia, the Southern and Northern Districts of Mississippi, and the United States Court of Federal Claims.

Accutane Information
Fosamax
Medtronic Defibrillator Recalls
Defective Heart Device